Interview: Akari's Coversin Ticking Along Nicely

10:56 EDT 11 Oct 2019 | SCRIP

The C5 complement inhibitor class is in the news following UCB's bid for Ra Pharmaceuticals. Akari's CEO tells Scrip he...


Related Stories


Original Article: Interview: Akari's Coversin Ticking Along Nicely


More From BioPortfolio on "Interview: Akari's Coversin Ticking Along Nicely"

Quick Search

Relevant Topic

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...